NAMED CAPABILITY · CNS AND AGGREGATION
NAMED CAPABILITY
CNS and aggregation
Neurodegeneration programs turn on aggregation. We run the assays that show whether a molecule changes it, and we bring the biology to read them.
What we carry
Aggregation and ThT
Aggregation kinetics
Cell culture
Cell-based and puncta assays
Binding assays
ELISA and titration
Molecular dynamics
Does the complex hold together?
Targets we work on
- Tau
- Alpha-synuclein
- TDP-43
- Amyloid-beta
We make the monomer too
Aggregation work is only as good as the starting material, so we generate the monomer ourselves rather than starting from whatever a vendor shipped. We express and purify the monomeric protein, confirm it is monomeric before the run, and then take it through controlled aggregation. That means the seed, the substrate and the timeline are all ours, and a result can be traced back to material we prepared.
Background
Our work includes a PhD on tau fibrils and experience across a clinical-stage neuroscience antibody portfolio.